Summary
Edwards Lifesciences (EW) filed an 8-K on February 1, 2018, to report its fourth-quarter 2017 financial results. While the 8-K itself is brief, it incorporates by reference a press release (Exhibit 99.1) containing the detailed financial performance for the period ending December 31, 2017. Investors should refer to this press release for specific figures regarding revenue, profitability, and any forward-looking guidance provided by the company. This filing signals the company's regular cycle of financial reporting and provides the market with an update on its operational and financial condition.
Key Highlights
- 1The 8-K filing officially reports Edwards Lifesciences' financial results for the fourth quarter of 2017.
- 2The detailed financial results are provided in an attached press release (Exhibit 99.1), which is incorporated by reference.
- 3The filing occurred on February 1, 2018, with the event date being January 31, 2018.
- 4This report pertains to the company's financial performance and condition.
- 5Information furnished under Item 2.02 is not considered 'filed' for the purposes of the Securities Exchange Act of 1934.
- 6Investors need to review the furnished press release for specific financial metrics and performance details.
Frequently Asked Questions
The primary purpose of this 8-K filing is to officially report Edwards Lifesciences' financial results for the fourth quarter of 2017 to the investing public.
The specific financial results, including revenue and earnings for the fourth quarter of 2017, are detailed in the press release (Exhibit 99.1) that is furnished with this 8-K filing and incorporated by reference.
When information is 'furnished' under Item 2.02, it means the company is providing it to the SEC for public disclosure but it does not carry the same legal implications or liabilities as information that is formally 'filed' under other sections of the Exchange Act.
Forward-looking statements and guidance for the upcoming periods would typically be found within the press release (Exhibit 99.1) itself, not in the brief 8-K form. Investors should consult that document for any such information.